Review of pathology data for regulatory purposes

Area of Science:

• Toxicologic pathology
• Regulatory science
• Drug safety evaluation

Background:

• Regulatory submissions require comprehensive pathology data for compound safety assessment.
• Independent review by regulatory agencies ensures data integrity and accurate interpretation.
• Standardized pathology data reporting is crucial for efficient regulatory review.

Purpose of the Study:

• To describe the pathology data review process at the Food and Drug Administration's Division of Pathology.
• To highlight common challenges and considerations in evaluating toxicologic pathology data.
• To provide recommendations for improving pathology data reporting to facilitate regulatory review.

Main Methods:

• Independent evaluation of submitted pathology data for agreement, terminology, and adequacy.
• Microscopic slide examination for lesion characterization and incidence verification.
• Analysis of common problems encountered during the regulatory pathology review process.

Main Results:

• Systematic review identifies discrepancies in data summarization, lesion terminology, and information adequacy.
• Microscopic slide review confirms or refutes findings and verifies lesion incidence.
• Common issues include data inconsistencies and challenges in lesion characterization.

Conclusions:

• The Division of Pathology's review process ensures independent and thorough evaluation of pathology data.
• Addressing common review challenges can improve the quality and efficiency of regulatory submissions.
• Clearer reporting guidelines for pathology data are recommended to facilitate regulatory review and compound safety assessment.